

Inhibition of HIV-1 replication by RNA targeted against the LTR region

Elena Puerta-Fernández^a, Alicia Barroso-del Jesus^a, Cristina Romero-López^a, Natalia Tapia^b, Miguel Angel Martínez^b and Alfredo Berzal-Herranz^a

Objective: The use of small RNA molecules able to effect gene inactivation has emerged as a powerful method of gene therapy. These small inhibitory RNAs are widely used for silencing malignant cellular and viral genes. We have assayed a series of inhibitory RNAs named catalytic antisense RNAs, consisting of a catalytic domain, hairpin or hammerhead ribozyme, and an antisense domain. The aim of the present study was to evaluate the effect of these inhibitory RNAs on HIV-1 replication.

Methods: A series of expression vectors has been constructed for the intracellular synthesis of inhibitory RNAs, differing in the promoter that drives their synthesis. These inhibitory RNAs were designed to act at two possible cleavage sites in the long terminal repeat (LTR) region and the TAR domain was chosen as a target for the antisense domain. We have evaluated the effects of different inhibitory RNAs in HIV replication via changes in p24 antigen levels. Mobility shift assays have been used to check the binding capacity of inhibitory RNAs.

Results: Catalytic antisense RNA designed to target the LTR region of HIV-1 inhibited viral replication in an eukaryotic cell environment by more than 90%. The conventional hairpin and hammerhead ribozymes, however, failed to inhibit viral replication.

Conclusions: The data provide preliminary evidence of a new class of inhibitory RNAs that can be used to block HIV replication. The results clearly show the importance of the *ex vivo* antisense effect in the inhibition achieved. A good correlation was found between the *in vitro* binding efficiency of the inhibitor RNA to the HIV-1 LTR and the inhibition of viral replication.

© 2005 Lippincott Williams & Wilkins

AIDS 2005, **19**:863–870

Keywords: ribozymes, catalytic antisense RNA, anti-HIV RNA, HIV therapy, inhibitory RNA

Introduction

The generation of RNA-based molecular tools with applications in biotechnology and medicine is currently of great interest. Allosteric ribozymes have emerged as powerful tools for the production of biosensors [1,2], antisense RNAs and RNA decoys have been successfully used for silencing cellular and viral genes [3–7], ribozymes have been designed to specifically cleave or

repair RNA substrates (reviewed in [8]), and small inhibitory (si)RNAs are now routinely used for knocking out genes in various organisms (reviewed in [9]).

HIV-1 RNAs have been favorite targets in the development of inhibitory RNA. Ribozymes [10–12], antisense RNAs [13–15], RNA decoys [6,16–18] and siRNAs [19,20] have all been designed to specifically target different viral genes, as well as cellular genes

From the ^aInstituto de Parasitología y Biomedicina “López-Neyra”, CSIC, Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento s/n, Armilla, 18100 Granada, Spain, and the ^bRetrovirology Laboratory IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain.

Correspondence to A. Berzal-Herranz, Instituto de Parasitología y Biomedicina “López-Neyra” CSIC. Parque Tecnológico de Ciencias de la Salud, Avda del Conocimiento s/n, Armilla, 18100 Granada, Spain.

E-mail: aberzalh@ipb.csic.es

Received: 30 July 2004; revised: 27 January 2005; accepted: 2 February 2005.

necessary for viral replication [21]. Current HIV-1 therapy is based on the use of a combination of different antiviral agents aimed at reducing plasma viral load and improving patient quality of life [22–24]. The same principle is adhered to in RNA-based antiviral approaches. A strategy to overcome the great variability of the virus is to combine the use of different ribozymes with different specificities [25,26]. Some authors have also described the effectiveness of combining different inhibitor RNA to fight HIV-1 infection [20,27].

The HIV-long terminal repeat (LTR) region plays an important role in the viral cycle [28], and so it is often chosen as a target for inhibitory RNAs [14,29–31]. The LTR region acts as a promoter of viral transcription and has been described as a regulatory checkpoint for controlling different leader functions through changes in its conformation [32].

Our group developed and characterized *in vitro* the catalytic antisense RNAs [33,34], a new class of inhibitory RNAs. These are hybrid molecules composed of a catalytic motif (hairpin or hammerhead ribozymes) and a stem–loop antisense motif. The latter, complementary to a stem–loop domain present in the corresponding substrate molecule, is covalently linked to the 3' end of the ribozyme. Catalytic antisense RNAs combine two inhibitory features: they bind efficiently to the substrate RNA (antisense effect) and catalyze its specific cleavage. We have demonstrated *in vitro* the ability of the catalytic antisense RNAs to cleave HIV-1 LTR RNA, using TAR as an anchoring site [34]. The inhibitory RNAs used consisted of a TAR complementary domain, named α TAR, linked to a hairpin (HP) or hammerhead (HH) ribozyme specifically designed to cleave the LTR region at positions +113 and +159. These two sites were previously shown to be effective targets for these catalytic motifs [29,35]; we demonstrated that the catalytic antisense RNAs cleave the LTR region more efficiently than conventional ribozymes at either of these positions [33,34]. Moreover, they showed improved substrate binding and gained better access to their target sequences inside folded RNA. Here we provide preliminary evidence of a new class of inhibitory RNAs. We report that these catalytic antisense RNAs achieve up to 90% inhibition of HIV-1 replication in eukaryotic cells, as measured by reductions in p24 levels.

Materials and methods

Construction of the anti-LTR catalytic antisense RNAs expression vectors

CMV-derived vectors

CMV-derived vectors were obtained by cloning the catalytic antisense RNA coding sequences between the *EcoRI* and *XbaI* sites of the pcDNA3 vector (InvitroGen). This vector contains the cytomegalovirus (CMV)

promoter as well as the BGH polyA sequence. The inhibitory RNA coding sequences were obtained from the previously described pG3HP113 α TAR, pG3HP159 α TAR, pG3HH113 α TAR and pG3HH159 α TAR vectors [34]. The vectors in this series were named pcHP113 α TAR, pcHP159 α TAR, pcHH113 α TAR and pcHH159 α TAR.

tRNA-derived vectors

tRNA^{Val}-derived vectors were obtained by cloning the catalytic antisense RNA coding sequences between the *KpnI* and *EcoRV* sites of the pUC-tRNA/KE vector [36], kindly provided by Dr. K Taira (University of Tokyo). This vector contains the tRNA^{Val} promoter as well as a linker sequence that ensures appropriate transcript folding for ribozyme activity and localization [36]. Inhibitory RNA coding sequences were obtained by PCR amplification from the CMV-derived vectors using primers 5'-HP113U6 (5'-ATATGCGGTACCACAA CAAGAAGGCAACCA-3'), 5'-HP159U6 (5'-ATATG CCGTACCCACACTAGAAGCAAACCA-3'), 5'-HH113U6 (5'-ATATGCGGTACCACAACACTGATGAGTCCG-3') or 5'-HH159U6 (5'-ATATGCGGTACC CACTCTGATGAGTCCG-3') and 3'-RzstRNA (5'-ATATGCGATATCGGATCCGGGTCTCTCTG-3'; restriction sites underlined).

U6-derived vectors

The pU6 vector was obtained by cloning the U6 promoter sequence [37] into the *BglII* and *DraIII* sites of pcDNA3. The U6 gene cassette used for its expression contains the sequence upstream of the human U6 gene from positions –1 to –265, the U6 RNA sequence from nucleotides +1 to +27, and a 3' stem as a transcript terminator. This vector ensures a high level of transcription, nuclear localization, and high intracellular stability [37]. The restriction sites used for cloning the inhibitory RNA into the pU6 vector were *KpnI* and *ApaI*. pU6-derived vectors were therefore obtained by cloning different inhibitory RNA coding sequences between the *KpnI* and *ApaI* restriction sites. Catalytic antisense RNAs coding sequences were obtained by amplifying the CMV-derived vectors with the already described primers 5'-HP113U6, 5'-HP159U6, 5'-HH113U6 or 3'-HH159U6, and 3'-RzsU6 (5'-ATATGCGGGCCC GGATCCGGGTCTCTCTG-3'; site underlined is *ApaI*). The vectors obtained were named pU6HP113 α TAR, pU6HP159 α TAR, pU6HH113 α TAR and pU6HH159 α TAR. The α TAR coding sequence present in vectors pU6HP159 α TAR and pU6HH113 α TAR was eliminated to yield the pU6HP159 and pU6HH113 control vectors. These were used to determine the intracellular activity of conventional HP159 and HH113 ribozymes. Vectors pU6HP159mut α TAR and pU6HH113mut α TAR, used for the expression of the inactive catalytic antisense RNA, were obtained by cloning the inactive ribozyme coding sequences between the *KpnI* and *BglIII* sites of pU6HP159 α TAR and pU6HH

113 α TAR respectively. The HP159mut coding sequence was obtained by the annealing and extension [33] of the primer pair 5'-HP159U6 and 3'-HPmut (5'-CAAGATCTTACCAGGAGATGTACCACGACTTATA CGTCGTGTGTTT-3'; mutations introduced to avoid catalytic activity are underlined). The annealing and extension of primers 5'-HH113mutU6 (5'-GGGTAC-CACAACACTAATGAGTCCGTGAGG-3') and 3'-HH113mutU6 (5'-CAAGATCTTGCCCGTTTCGT CCTCACGGACTC-3') was undertaken to obtain the HH113mut coding sequence.

To obtain the pU6 α TAR vector, the α TAR coding sequence was obtained by the annealing and extension of the primer pair 5' α TARU6 (5'-CGGGTCCCTAGT TAGCCAGAGAGCTCCAGGCTCAAATCTGGTCTAACCAGAGAGACCCGGGCC-3') and 3' α TARU6 (5'-CGGGTCTCTCTGGTTAGACCAGATTTGAG CCTGGGAGCTCTCTGGCTAACTAGGGAACCCGGTAC-3'). Oligonucleotides were previously phosphorylated with T4-polynucleotide kinase (New England Biolabs) and the resulting product (which already has *KpnI*-*ApaI* compatible ends) cloned into the pU6 vector.

Determination of inhibitory RNA intracellular activity

The U87-CD4-CXCR4 glioma cell line [38] was used to assay the activity of the inhibitory RNA. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 50 000 U/l penicillin and 50 mg/l streptomycin. Cells (1×10^5) were co-transfected with 0.5 μ g inhibitory RNA-expressing vector, and 1 μ g pNL4-3 proviral DNA, using the LipofectAMINE-2000 reagent (Life Technologies, London, UK). Controls were performed by transfecting 0.5 μ g of the empty vector and 1 μ g of the pNL4-3 plasmid. Five days after transfection, HIV-1 replication in control cells, and in cells expressing the inhibitory RNAs, was evaluated by determining p24 release. This was done in duplicate using a commercial p24 antigen enzyme-linked immunosorbent assay kit (Innogenetics, Madrid, Spain). All assays were performed twice. To calculate the inhibitory effect of the different inhibitory RNA, the amount of p24 antigen determined for the control sample (empty vector-transfected) was normalized to 100, and the results for test samples converted to a corresponding percentage. All calculations were made using data from at least three replicates.

In vitro binding assays

Catalytic antisense RNAs and LTR substrate RNA were obtained by *in vitro* transcription as previously described [34]. The α TAR coding sequence was obtained by PCR amplification of the plasmid pU6HP159 α TAR with the oligonucleotides P1-5'-TAR(-10) (5'-GCCAATTC TAATACGACTCACTATAGGGGGTCCCTAGT TAGCC-3') and P2-3'-TAR(-10) (5'-GCGGATCCGG GTCTCTCTGGTTAGA-3'). The resulting product,

which already has the T7 promoter (underlined), was used as a template for the *in vitro* transcription reaction to yield the α TAR RNA.

Electrophoretic mobility shift assays were performed in 5% (w/v) TBE native polyacrylamide gels at 4°C. The dissociation constant (*K_d*) of the different inhibitory RNA-LTR complexes was deduced from the shift of 2 nM [³²P]-5' end-labeled LTR RNA in the presence of increasing concentrations of the inhibitory RNAs. Different RNA molecules were separately renatured by incubating in binding buffer (Tris-HCl 50 mM pH 7.5, 10 mM MgCl₂) at 65°C for 10 min, and at 37°C for 10 min. Reactions were initiated by combining both molecules and performed on ice to avoid ribozyme cleavage activity. Complex formation was quantified using a Storm 820 instrument (Amersham Biosciences). The *K_d* was extracted from data point fitting using SigmaPlot 8.0 software, according to the equation $y = ax / b + x$, where *y* represents the percentage of complex formation, *x* is the inhibitor concentration, *a* represents the maximum percentage of complex, and *b* corresponds to the dissociation constant (*K_d*).

Results

Intracellular activity of the anti-LTR catalytic antisense RNAs

We previously described the capacity of the anti-LTR catalytic antisense RNAs, HH113 α TAR, HH159 α TAR, HP113 α TAR and HP159 α TAR ([33,34]; Fig. 1) to cleave LTR RNA *in vitro*. Both the catalytic and the antisense RNA domains of the hybrid inhibitory molecule target the HIV-1 LTR; the catalytic motif is designed against positions 113 (HH113 and HP113) and 159 (HH159 and HP159), and the TAR domain is the target of the antisense motif (α TAR). TAR acts as an anchoring site of the inhibitory RNA by binding to the complementary stem-loop motif (antisense domain α TAR) in the substrate molecule. The target sequences were selected based on their high conservation among different HIV isolates, as well as on the defined substrate sequence requirements of the ribozymes [39-41].

To assay the intracellular activity of the catalytic antisense RNAs, we generated series of constructs in which the synthesis of these RNAs was driven by pol II or pol III promoters. Different expression vectors based on RNA polymerase II (pol II) or III (pol III) promoters are widely used to achieve optimum levels of small RNA molecules in the appropriate intracellular compartment [42]. We chose the CMV immediate early promoter as the pol II promoter, and the tRNA and U6 promoters as pol III promoters. The tRNA promoter sequence is the tRNA^{Val} sequence described for the intracellular expression of hammerhead ribozymes [36], whereas




Fig. 1. Anti-LTR catalytic antisense RNAs. (a) Sequence and secondary structure model for the anti-LTR hairpin-derived catalytic antisense RNAs (HP). The catalytic domain (shaded) is derived from the (-)sTRSV hairpin ribozyme. The antisense domain is the TAR complementary stem-loop domain (α TAR). Nucleotides in the substrate binding arms of the catalytic domains are shown with bold NS. The specific sequences used for targeting positions 113 (HP113) and 159 (HP159) in the HIV-1 LTR region are also shown boxed. The encircled nucleotides were mutated to generate catalytically inactive molecules. (b) Anti-LTR hammerhead-derived catalytic antisense RNAs (HH). The catalytic domain (shaded) is derived from the (+)sTRSV hammerhead ribozyme. The α TAR RNA is the antisense domain. Bold nucleotides are those corresponding to the hammerhead substrate binding arms. Sequences for targeting the LTR RNA in positions 113 (HH113) and 159 (HH159) are shown boxed. The encircled nucleotides were mutated to generate catalytically inactive molecules. (c) Nucleotide sequence of NL4.3 HIV-1 strain. Nucleotides from +1 to 305 are shown. Bold letters correspond to TAR domain. Shaded nucleotides are the substrate target sites 113 and 159 recognized by the ribozymes. Arrowheads indicate the cleavage site of the hairpin catalytic domains (solid) and the hammerhead ones (empty). (d) Schematic representation of the hypothesized action of the catalytic antisense RNAs. Potential pathway of interactions between the catalytic antisense RNA and the LTR substrate molecule is outlined. Note that the molecules are not drawn to scale. Substrate binding domain of the catalytic domain is encircled. Arrowhead indicates the site of cleavage. Grey box represents target sequences within the substrate RNA (113 or 159 in this work).




Fig. 2. Intracellular activity of catalytic antisense RNAs. Antigen p24 levels obtained on day 5 after co-transfection of pNL4-3 and the corresponding inhibitor-expressing vector in U87-CD4-CXCR4 cells. The promoter used in each case is indicated. Numbers represent the different inhibitor RNA coding sequences tested. 0: empty vector; 1: HH113 α TAR; 2: HH159 α TAR; 3: HP113 α TAR; 4: HP159 α TAR. The percentage of inhibition achieved, normalized with respect to the value obtained for the control, is shown above each bar. Values represent the mean \pm SD of two experiments.

the U6 promoter construct is a modification of that described by Engenkel *et al.* [37] (see Materials and methods). Thus, three different plasmids were generated for each of the catalytic antisense RNAs to be assayed (see Materials and methods).

The 12 inhibitory RNA-expressing constructs were challenged with the pNL4-3 plasmid containing HIV-1 NL4-3 proviral DNA. Different plasmids were co-transfected with pNL4-3 into U87-CD4-CXCR4 mammalian cells (see Materials and methods). Transfection with plasmid pNL4-3 allowed a normal viral replication cycle. The ability of the different RNAs to inhibit HIV-1 expression was measured in terms of their capacity to reduce p24 production (Fig. 2). Day 5 was the optimum time for measuring p24 levels. The inhibitory effect could be maintained in cells cultured for up to 6 days after transfection (data not shown). The catalytic antisense RNAs synthesized under the control of the U6 promoter resulted in the highest rates of inhibition. A reduction of almost two orders of magnitude in p24 levels was achieved with HH113 α TAR and HP159 α TAR compared to the control. No significant inhibition was obtained with the RNAs synthesized from the tRNA or CMV promoter constructs, with the exception of the HH113 α TAR molecule synthesized under the control of the CMV promoter, which caused an 80% reduction in p24 levels.

Inhibitory contribution of the catalytic and antisense domains

To analyze further the contribution of each inhibitory domain to the inhibition shown by the two most active molecules (HH113 α TAR and HP159 α TAR), we assayed a series of RNA molecules derived from each. Plasmids encoding the conventional hammerhead and hairpin ribozymes (HH113 and HP159), as well as catalytically

non-active derivatives (HH113mut α TAR and HP159mut α TAR; [33,34]; Fig. 1) were constructed under the control of the U6 promoter. The ability of these molecules to inhibit viral replication, plus that of the antisense domain (α TAR) by itself, was tested as described above (Fig. 3). No obvious defects were observed at day 5 in cells transfected only with plasmids encoding the inhibitory RNAs. Interestingly, neither the HH113 nor the HP159 ribozymes showed any significant inhibition of replication, showing that conventional ribozymes fail to reduce viral replication under these conditions. For the HH113-derived catalytic antisense RNAs, the active molecule (HH113 α TAR) showed appreciable activity, causing some 70% inhibition. Surprisingly, the best results were obtained with the molecule whose catalytic activity had been abolished (HH113mut α TAR). This molecule showed a reduction in p24 levels of > 90%. With respect to the catalytic antisense RNAs derived from the HP159 ribozyme, the best results were obtained with the active molecule (HP159 α TAR)-with > 90% reduction in p24 production. The activity of the HP159mut α TAR molecule was quite significant as well (nearly 80%). These results indicate that the intracellular inhibitory capacity of these molecules is due mainly to an antisense effect, and is therefore independent of the molecule's catalytic activity. The α TAR molecule itself, however, was unable to reduce viral replication under the same conditions (Fig. 3), demonstrating that the ribozyme domain – active or inactive – in the catalytic antisense RNAs is required for inhibition to be achieved.

In vitro binding of the catalytic antisense RNAs

The intracellular results show that the inhibition achieved by these chimeric molecules is owed mainly to an antisense effect. The surprising results obtained with the HH113mut α TAR molecule led us to examine its




Fig. 3. Inhibition of HIV replication by U6-driven catalytic antisense RNAs. Inhibition of viral replication obtained by different HH113- and HP159-derived catalytic antisense RNAs. The percentage inhibition achieved, normalized with respect to the value obtained for the control, is shown above each bar. Values are the mean \pm SD of at least three independent experiments. Rz, conventional ribozyme; RNAAS, catalytic antisense RNA; RNAASmut, mutated catalytic antisense RNA.

inhibitory features further. This molecule has the same sequence as HH113 α TAR, except that the nucleotide G5 in the hammerhead core is mutated to A (Fig. 1b) to impede cleavage activity. This residue has been shown essential for ribozyme activity, and it seems to be involved in the folding of the ribozyme after binding to the substrate [43]. HH113mut α TAR-RNA was unable to cleave the LTR RNA *in vitro* (data not shown). To analyze its binding capacity, mobility shift assays were performed (Fig. 4) and the results compared with those obtained for the active molecule HH113 α TAR. Reactions were performed on ice to avoid the cleavage activity of the HH113 α TAR molecule. Under these conditions, HH113mut α TAR showed a higher binding efficiency than the corresponding active molecule (Table 1). The binding activity of the HP159 α TAR and HP159mut α TAR molecules was also compared, and the results show that the active molecule binds the LTR RNA more efficiently than the catalytically null molecule (Table 1). The binding of the antisense domain α TAR molecule to the target LTR was also assayed, and showed a very poor binding rate (Table 1). Therefore, under these conditions, the molecules that bind to LTR RNA most efficiently are those whose intracellular inhibitory effect is highest.

Discussion

This work shows the ability of catalytic antisense RNAs to inhibit HIV-1 replication in mammalian cells. These molecules showed greater inhibition of p24 production than their ribozyme motif on its own. This agrees with previous *in vitro* characterization studies [34] in which these inhibitory molecules processed the LTR RNA more efficiently than the catalytic motifs alone, validating this strategy for optimizing ribozyme design. The results in Fig. 2 correlate well with the *in vitro* cleavage efficiencies obtained; HP159 α TAR and HH113 α TAR were the most efficient inhibitors in cells. We cannot conclude whether the inhibitor RNAs are acting on 3' or 5' LTR. In the above earlier studies [34], we showed that the antisense motif promoted effective anchorage of the inhibitory molecule to the substrate, allowing its catalytic part to efficiently reach its target site inside folded RNA molecules. In this work, assaying the inhibition of viral replication inside cells, a strong inhibitory antisense effect was seen. Such an effect might indicate that the binding of the antisense domain to TAR may also interfere with the biologically important roles of TAR (e.g., binding of Tat protein to the TAR motif, challenging the transactivation




Fig. 4. Electrophoretic mobility shift assays. Labeled LTR RNA was incubated with unlabeled inhibitor RNAs at 4°C for 90 min. Aliquots were removed at the indicated time intervals. The figure shows the binding between LTR RNA and HH113-derived catalytic antisense RNAs. Complexes, shown by arrows, migrate less than the LTR RNA.

Table 1. K_d values for the different catalytic antisense RNAs.

	HH113 α TAR	HH113mut α TAR	HP159 α TAR	HP159mut α TAR	α TAR
K_d (nM) ^a	n.d. ^b	34.0331 \pm 6.47	53.2208 \pm 2.1837	n.d.	n.d.

^aValues are the means of at least four independent trials \pm SD.

^bn.d. not determined: concentrations up to 800 nM were tested but complex formation was not appreciated.

of transcription). It has been reported that U6 promoter leads to nuclear localization of the resulting RNAs [37,44], whereas the other promoters assayed (tRNA and CMV) lead to preferentially cytoplasmic localization of the transcripts [36,42]. The observed inhibition differences might be explained by the different subcellular localization of the inhibitory RNAs. This may suggest a post-integration inhibitory effect achieved by RNAs synthesized under the control of the U6 promoter, but we cannot rule out any other possibility.

A comparison of the inhibitory features of the catalytically active and inactive RNA molecules shows that the intracellular inhibitory capacity of these molecules is independent of their catalytic action. With respect to the HH113-derived catalytic antisense RNAs, HH113mut α TAR caused more than a 90% reduction in p24 levels. The active molecule (HH113 α TAR) showed substantially lower inhibitory activity, although it was still very significant (Fig. 3). Such differences might be explained by the different binding behavior of these active and inactive variants. The molecule HH113mut α TAR was able to bind to the substrate more efficiently than the HH113 α TAR molecule. This result correlates well with the data obtained from comparisons of the binding of the HP159-derived catalytic antisense RNAs (Fig. 4, Table 1), suggesting that the inhibitory capacity of the catalytic antisense RNAs *ex vivo* is determined by their ability to bind to HIV RNA. Although all the RNAs used have the same α TAR domain as the antisense motif, their antisense effect was different depending on their overall structure—the inhibitory effect of each therefore differed. Thus, the inhibition achieved seems to be an intrinsic feature of the complete RNA molecule rather than being owed to any specific domain. This is further supported by the fact that none of the ribozymes used, nor the α TAR on its own, showed any significant inhibitory activity.

Studies performed with natural antisense RNA systems show that antisense RNAs with complementarity to their target sequences in the stem–loop domain can establish kissing-complexes, but do not go on to form more stable complexes [45]. Complementary nucleotides in single-stranded regions adjacent to the stem–loop are required for these more stable complexes to form [45]. In our system, the α TAR molecule shows complementarity only to the TAR stem–loop, making the formation of a stable complex more difficult. Nevertheless, the catalytic antisense RNAs (active or inactive) were able to bind to

the LTR region through the stem–loop domain and the substrate-binding domain of the ribozyme, which might facilitate progress from the initial complex towards a more stable one. This is supported by the data obtained from the binding assays. Such binding increases their antisense inhibitory capacity and their *ex vivo* anti-HIV-1 activity. Further analysis is required to confirm this mechanism.

Conclusion

This work provides preliminary evidence of a new class of inhibitory RNAs. It shows the inhibition of HIV replication exerted by catalytic antisense RNA targeted against the LTR region. Further, the *ex vivo* capacity of these RNAs to block viral replication correlates well with their ability to bind the HIV substrate *in vitro*. These results may help establish general rules for the design of new antiviral—in particular anti-HIV-1—agents based on RNA molecules.

Acknowledgments

We thank V. A. Vacas for excellent technical assistance. We are also grateful to Dr. Taira (University of Tokio) for the plasmid pUCtRNA/KE. The pNL4-3 plasmid DNA was obtained from M. Martin and the U87-CD4-CXCR4 cells from H.K. Deng and D. Littman through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.

E.P.-F. was partially supported by a fellowship from the Spanish Ministerio de Educación y Cultura. *A.B.-delJ.* and *C.R.-L.* are the recipients of a CSIC-I3P program contract and fellowship respectively, funded by the European Social Funds. This work was supported by grants from the Spanish Fundación FIPSE (36266.02) and the Ministerio de Ciencia y Tecnología (BMC2003-669) to *A.B.-H.* Work at IrsiCaixa was supported by grants from the Ministerio de Educación y Ciencia (BCM 2003-02148) and the Spanish Fondo de Investigación Sanitaria (“Red Temática de Investigación en SIDA, RIS).

References

1. Soukup GA, Breaker RR. **Nucleic acid molecular switches.** *Trends Biotechnol* 1999; **17**:469–476.
2. Breaker RR. **Engineered allosteric ribozymes as biosensor components.** *Curr Opin Biotechnol* 2002; **13**:31–39.

3. Engdahl HM, Hjalt TA, Wagner EG. **A two unit antisense RNA cassette test system for silencing of target genes.** *Nucl Acids Res* 1997; **25**:3218–3227.
4. Homann M, Rittner K, Sczakiel G. **Complementary large loops determine the rate of RNA duplex formation in vitro in the case of an effective antisense RNA directed against the human immunodeficiency virus type 1.** *J Mol Biol* 1993; **233**:7–15.
5. Makeyev AV, Eastmond DL, Liebhaber SA. **Targeting a KH-domain protein with RNA decoys.** *RNA* 2002; **8**:1160–1173.
6. Michienzi A, Li S, Zaia JA, Rossi JJ. **A nucleolar TAR decoy inhibitor of HIV-1 replication.** *Proc Natl Acad Sci USA* 2002; **99**:14047–14052.
7. Cassiday LA, Maher LJ 3rd. **Yeast genetic selections to optimize RNA decoys for transcription factor NF-kappa B.** *Proc Natl Acad Sci USA* 2003; **100**:3930–3935.
8. Puerta-Fernandez E, Romero-Lopez C, Barroso-delJesus A, Berzal-Herranz A. **Ribozymes: recent advances in the development of RNA tools.** *FEMS Microbiol Rev* 2003; **27**:75–97.
9. Denli AM, Hannon GJ. **RNAi: an ever-growing puzzle.** *Trends Biochem Sci* 2003; **28**:196–201.
10. Macpherson JL, Ely JA, Sun LQ, Symonds GP. **Ribozymes in gene therapy of HIV-1.** *Front Biosci* 1999; **4**:D497–D505.
11. Wang DY, Sen D. **Rationally designed allosteric variants of hammerhead ribozymes responsive to the HIV-1 Tat protein.** *Comb Chem High Throughput Screen* 2002; **5**:301–312.
12. Zaira JA, Cantin EM, Chang PS, Sarver N, Rossi JJ. **Antiviral Evaluation of HIV-1 Specific Ribozyme Expressed in CD4+ HeLa Cells.** In: *Advances in Molecular Biology and Targeted Treatment for AIDS.* Edited by Kumar A. New York: Plenum Press; 1991. pp. 335–343.
13. Veres G, Junker U, Baker J, Barske C, Kalfoglou C, Ilves H, et al. **Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication.** *J Virol* 1998; **72**:1894–1901.
14. Chadwick DR, Lever AM. **Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.** *Gene Ther* 2000; **7**:1362–1368.
15. Ding SF, Noronha J, Joshi S. **Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.** *Nucl Acids Res* 1998; **26**:3270–3278.
16. Bohjanen PR, Colvin RA, Puttaraju M, Been MD, Garcia-Blanco MA. **A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription.** *Nucl Acids Res* 1996; **24**:3733–3738.
17. Fraissier C, Irvine A, Wrighton C, Craig R, Dzierzak E. **High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.** *Gene Ther* 1998; **5**:1665–1676.
18. Konopka K, Lee NS, Rossi J, Duzgunes N. **Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication.** *Gene* 2000; **255**:235–244.
19. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, et al. **Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.** *AIDS* 2002; **16**:2385–2390.
20. Li MJ, Bauer G, Michienzi A, Yee JK, Lee NS, Kim J, et al. **Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.** *Mol Ther* 2003; **8**:196–206.
21. Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schumperli D. **Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.** *Nucl Acids Res* 2004; **32**:3752–3759.
22. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. **Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.** *Science* 1997; **277**:112–116.
23. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. **Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.** *N Engl J Med* 1998; **338**:853–860.
24. Ho DD. **Toward HIV eradication or remission: the tasks ahead.** *Science* 1998; **280**:1866–1867.
25. Chen CJ, Banerjee AC, Harmison GG, Haglund K, Schubert M. **Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates.** *Nucl Acids Res* 1992; **20**:4581–4589.
26. Ohkawa J, Yuyama N, Takebe Y, Nisikawa S, Homann M, Sczakiel G, et al. **Multiple site-specific cleavage of HIV RNA by transcribed ribozymes from shotgun-type trimming plasmid.** *Nucl Acids Symp Ser* 1993; **29**:121–122.
27. Gervaix A, Li X, Kraus G, Wong-Staal F. **Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades.** *J Virol* 1997; **71**:3048–3053.
28. Berkhout B. **Structure and function of the human immunodeficiency virus leader RNA.** *Prog Nucleic Acid Res Mol Biol* 1996; **54**:1–34.
29. Bramlage B, Luzi E, Eckstein F. **HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.** *Nucl Acids Res* 2000; **28**:4059–4067.
30. Arzumanov A, Walsh AP, Rajwanshi VK, Kumar R, Wengel J, Gait MJ. **Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2'-O-methyl/LNA oligoribonucleotides.** *Biochemistry* 2001; **40**:14645–14654.
31. Koizumi M, Ozawa Y, Yagi R, Nishigaki T, Kaneko M, Oka S, et al. **Design and anti-HIV-1 activity of hammerhead and hairpin ribozymes containing a stable loop.** *Nucleosides Nucleotides* 1998; **17**:207–218.
32. Berkhout B, Ooms M, Beerens N, Huthoff H, Southern E, Verhoef K. **In vitro evidence that the untranslated leader of the HIV-1 genome is an RNA checkpoint that regulates multiple functions through conformational changes.** *J Biol Chem* 2002; **277**:19967–19975.
33. Puerta-Fernandez E, Barroso-DelJesus A, Berzal-Herranz A. **Anchoring hairpin ribozymes to long target RNAs by loop-loop RNA interactions.** *Antisense Nucl Acid Drug Dev* 2002; **12**:1–9.
34. Puerta-Fernández E, Barroso-delJesus A, Romero-López C, Berzal-Herranz A. **HIV-1 TAR as anchoring site for optimized catalytic RNAs.** *Biological Chemistry* 2003; **384**:343–350.
35. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J. **Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme.** *Proc Natl Acad Sci USA* 1992; **89**:10802–10806.
36. Kato Y, Kuwabara T, Warashina M, Toda H, Taira K. **Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells.** *J Biol Chem* 2001; **276**:15378–15385.
37. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, et al. **Expression of small, therapeutic RNAs in human cell nuclei.** *Gene Ther* 1997; **4**:45–54.
38. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. **Identification of a major co-receptor for primary isolates of HIV-1.** *Nature* 1996; **381**:661–666.
39. Berzal-Herranz A, Joseph S, Chowrira BM, Butcher SE, Burke JM. **Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme.** *EMBO J* 1993; **12**:2567–2573.
40. Pérez-Ruiz M, Barroso-DelJesus A, Berzal-Herranz A. **Specificity of the hairpin ribozyme. Sequence requirements surrounding the cleavage site.** *J Biol Chem* 1999; **274**:29376–29380.
41. Kore AR, Vaish NK, Kutzke U, Eckstein F. **Sequence specificity of the hammerhead ribozyme revisited; the NHH rule.** *Nucl Acids Res* 1998; **26**:4116–4120.
42. Rossi JJ, Couture LA (eds). *Intracellular ribozyme applications. Principles and protocols.* Norfolk, UK: Horizon Scientific Press; 1999.
43. Hammann C, Lilley DM. **Folding and activity of the hammerhead ribozyme.** *ChemBiochem* 2002; **3**:690–700.
44. Carmo-Fonseca M, Pepperkok R, Carvalho MT, Lamond AI. **Transcription-dependent colocalization of the U1, U2, U4/U6, and U5 snRNPs in coiled bodies.** *J Cell Biol* 1992; **117**:1–14.
45. Persson C, Wagner EG, Nordstrom K. **Control of replication of plasmid R1: structures and sequences of the antisense RNA, CopA, required for its binding to the target RNA, CopT.** *EMBO J* 1990; **9**:3767–3775.